NVCHI
CORT icon

New Vernon Capital Holdings II’s Corcept Therapeutics CORT Stock Holding History

New Vernon Capital Holdings II’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,851
Closed -$168K – 32
2019
Q3 		$168K Buy
11,851
+512
+5% +$6.29K 0.12% 18
2019
Q2 		$126K Buy
+11,339
New +$126K 0.09% 15

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New Vernon Capital Holdings II's CORT Position: Q4 2019 in Review

New Vernon Capital Holdings II sold out of Corcept Therapeutics (CORT) in Q4 2019, closing a stake of 11,851 shares — an estimated $168K sold.

New Vernon Capital Holdings II first reported a position in CORT in Q2 2019 and held it in 2 quarters. The position peaked at $168K in Q3 2019. 205 funds tracked by Wall St. Rank hold CORT as of Q4 2019.

  • New Vernon Capital Holdings II reported no remaining Corcept Therapeutics position as of Q4 2019 after selling out during the quarter.
  • New Vernon Capital Holdings II sold 11,851 Corcept Therapeutics shares in Q4 2019, an estimated $168K.
  • New Vernon Capital Holdings II first reported a position in Corcept Therapeutics in Q2 2019 and held it in 2 quarters.
  • New Vernon Capital Holdings II's Corcept Therapeutics position peaked at $168K in Q3 2019.
  • 205 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2019.

Based on New Vernon Capital Holdings II's 13F filing for Q4 2019, filed 12 Feb 2020.